Synonym: 2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]-3-hydroxypropyl (2S)-2-amino-3-methylbutanoate hydrochloride hydrate; L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, monohydrochloride hydrate
CAS Number: 175865-59-5 (anhydrous)
Empirical Formula (Hill Notation): C14H22N6O5·HCl · xH2O
Molecular Weight: 390.82 (anhydrous basis)
Linear Formula: C14H22N6O5·HCl · xH2O
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts SML0191-10MG.
| assay |
≥98% (HPLC) |
| color |
white to tan |
| form |
powder |
| InChI |
1S/C14H22N6O5.ClH.H2O/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22;;/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22);1H;1H2/t8?,9-;;/m0../s1 |
| InChI key |
XASVRRIYQZVANH-AHBBCRTASA-N |
| originator |
Roche |
| Quality Level |
100  |
| SMILES string |
O.Cl.CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2C(=O)N=C(N)Nc12 |
| solubility |
H2O: ≥8 mg/mL |
| storage condition |
desiccated |
| storage temp. |
−20°C |
| Application: |
Valganciclovir hydrochloride hydrate may be used in HIV-related cell signaling studies. |
| Biochem/physiol Actions: |
Valganciclovir hydrochloride hydrate is an antiviral used to treat cytomegalovirus infection. It is the prodrug of ganciclovir, a synthetic analog of 2′-deoxy-guanosine which is phosphorylated to a dGTP analog that competitively inhibits the incorporation of dGTP by viral DNA polymerase. |
| Biochem/physiol Actions: |
Valganciclovir hydrochloride hydrate is an antiviral; prodrug for ganciclovir |
| Biochem/physiol Actions: |
Valganciclovir is a valine ester of Ganciclovir, used to treat cytomegalovirus retinitis in HIV-infected patients. It is rapidly metabolized to ganciclovir by hydrolysis before entering the systemic circulation resulting in improved absorption of the drug. |
| Features and Benefits: |
This compound was developed by Roche . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
10, 50 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
−20°C |
| UNSPSC |
12352200 |